Cartesian Therapeutics (RNAC) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Cartesian Therapeutics (RNAC) over the past year, gaining 62.9% versus a loss of 31.4%. Over five years, WHWK leads with a -87.2% price change compared with -94.8% for RNAC. Cartesian Therapeutics is the larger company by market cap ($206.3 million vs $197.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNAC | WHWK |
|---|---|---|
| Share price | $6.82 | $3.47 |
| Market cap | $206.34M | $197.82M |
| 1-day change | +2.10% | +1.76% |
| YTD return | -7.35% | +43.39% |
| 1-year return | -31.42% | +62.91% |
| 5-year return | -94.79% | -87.25% |
| EPS (TTM) | $-5.78 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.00 | $5.50 |
| 52-week low | $5.60 | $1.87 |
| Distance from 52-week high | -38.00% | -36.85% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +393.70% | +122.19% |
| Average volume | 133.50K | 367.72K |
| Shares outstanding | 30.26M | 57.01M |
| Employees | 75 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed RNAC by 94.3 percentage points over the past year.
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
RNAC vs WHWK FAQ
Which is bigger, Cartesian Therapeutics or Whitehawk Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $206.34M compared with $197.82M for Whitehawk Therapeutics (WHWK).
Which stock has performed better over the past year, RNAC or WHWK?
WHWK returned +62.91% over the past 12 months, compared with -31.42% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cartesian Therapeutics and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.